Don’t Miss These Key Interviews, Data At the International Myeloma Society 2024 Congress

The meeting will focus on the basic, preclinical, and clinical aspects of myeloma, including precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more.

Pharmacy Times will be covering the International Myeloma Society’s (IMS) 21st Annual Meeting, happening September 25 through 28 in Rio de Janeiro, Brazil. The meeting will focus on the basic, preclinical, and clinical aspects of myeloma, including precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more.

Aerial view of Christ and Botafogo Bay from high angle, Rio de Janeiro, Brazil

Rio de Janeiro | Image credit: marchello74 | stock.adobe.com

In addition to 6 thematic sessions, the meeting will include discussions and symposia led by key opinion leaders in the myeloma community, special sessions for trainees, keynote addresses, joint sessions with regulatory agencies, special sessions on minimal residual disease and new endpoints, and oral abstracts. Stay tuned on PharmacyTimes.com and follow along on social media for exclusive articles and interviews with experts.

In an interview with Pharmacy Times, keynote speaker Anant Matabhushi, PhD, executive director of the Emory Empathetic AI for Health Institute, will discuss the great potential for artificial intelligence (AI) in myeloma, including uses in treatment selection. Although tools are emerging for clinical decision support, Matabhushi said he sees a need for tools further downstream in post-diagnosis stages.
In a session on Wednesday, experts will discuss precursor disease, including monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Topics of interest in this session will include approaches to risk stratification for patients with high-risk myeloma, takeaways from the iStopMM (NCT03327597) study, and approaches for the management of SMM.
In a conversation with Pharmacy Times, presenter Rahul Banerjee, MD, FACP, discussed the growing list of options for T cell-directed therapies in myeloma and factors to consider when choosing a treatment regimen. Banerjee will also share his perspective on the crucial role for pharmacists as part of the myeloma care team.
In a session on Saturday, experts will convene to discuss how bispecific antibodies (BsAbs) are transforming the therapeutic landscape of relapsed multiple myeloma. In addition to treatment strategies for relapsed/refractory multiple myeloma with BsAbs, key opinion leaders will review the journey of BsAbs into the clinic setting and efficacy data regarding BsAbs in minority patients.
In a video interview, Ashraf Badros, MD, will discuss primary results from the phase 3 AURIGA (NCT03901963) study being presented at IMS. The AURIGA study evaluated subcutaneous daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in patients with newly diagnosed multiple myeloma after transplant.

Follow Pharmacy Times for these conversations and articles, and much more during the 2024 IMS Annual Meeting.